LeMaitre Vascular (NASDAQ:LMAT) Upgraded at Freedom Capital

Freedom Capital upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) to a hold rating in a research report report published on Tuesday morning,Zacks.com reports.

Several other brokerages have also recently issued reports on LMAT. Barrington Research upped their price target on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Weiss Ratings upgraded shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Roth Mkm restated a “buy” rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Finally, Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $105.80.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $108.49 on Tuesday. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of 43.22, a PEG ratio of 3.13 and a beta of 0.67. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. The business’s 50-day moving average price is $98.67 and its 200-day moving average price is $90.56. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. The company had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm’s revenue was up 15.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Equities research analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were given a $0.25 dividend. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date was Thursday, March 12th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is presently 39.84%.

Insider Activity

In other news, insider Trent G. Kamke sold 1,044 shares of the stock in a transaction on Friday, February 27th. The shares were sold at an average price of $110.29, for a total transaction of $115,142.76. Following the completion of the sale, the insider directly owned 6,677 shares in the company, valued at $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David B. Roberts sold 8,464 shares of LeMaitre Vascular stock in a transaction on Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the transaction, the director directly owned 17,979 shares of the company’s stock, valued at $1,920,157.20. This represents a 32.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 215,438 shares of company stock valued at $23,062,911. 9.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of LeMaitre Vascular by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after purchasing an additional 21,946 shares in the last quarter. First Trust Advisors LP increased its holdings in LeMaitre Vascular by 13.4% in the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock worth $76,245,000 after purchasing an additional 111,193 shares in the last quarter. State Street Corp lifted its stake in LeMaitre Vascular by 0.8% in the fourth quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock valued at $65,447,000 after buying an additional 6,130 shares during the period. Congress Asset Management Co. lifted its stake in LeMaitre Vascular by 5.8% in the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after buying an additional 40,065 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of LeMaitre Vascular by 20.1% during the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock worth $51,351,000 after buying an additional 105,921 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.